Literature DB >> 7758525

Prostacyclin aerosol in an infant with pulmonary hypertension.

B Santak1, M Schreiber, P Kuen, D Lang, P Radermacher.   

Abstract

Prostacyclin aerosol (100 ng/kg.min) caused selective pulmonary vasodilation without causing systemic hypotension in an infant with idiopathic pulmonary hypertension. Cardiac index increased suggesting improved right ventricular function. CONCLUSION Aerosolized prostacyclin causes selective pulmonary vasodilation and may thereby improve systemic haemodynamics in infants with primary pulmonary hypertension. Because of the lack of known toxicity and the uncomplicated mode of administration it may be a useful alternative to inhaled nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758525     DOI: 10.1007/BF01954279

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

2.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

3.  Nebulizer function during mechanical ventilation.

Authors:  T G O'Riordan; M J Greco; R J Perry; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1992-05

4.  Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

Authors:  L J Rubin; J Mendoza; M Hood; M McGoon; R Barst; W B Williams; J H Diehl; J Crow; W Long
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

5.  Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension.

Authors:  J Pepke-Zaba; T W Higenbottam; A T Dinh-Xuan; D Stone; J Wallwork
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

6.  Inhaled nitric oxide in congenital heart disease.

Authors:  J D Roberts; P Lang; L M Bigatello; G J Vlahakes; W M Zapol
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

7.  Selective and sustained pulmonary vasodilation with inhalational nitric oxide therapy in a child with idiopathic pulmonary hypertension.

Authors:  J P Kinsella; W H Toews; D Henry; S H Abman
Journal:  J Pediatr       Date:  1993-05       Impact factor: 4.406

8.  Aerosolised prostacyclin in adult respiratory distress syndrome.

Authors:  D Walmrath; T Schneider; J Pilch; F Grimminger; W Seeger
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

9.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

10.  Low dose inhaled nitric oxide causing selective pulmonary vasodilation in child with idiopathic pulmonary hypertension.

Authors:  P Radermacher; S Rammos
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

View more
  7 in total

1.  Eight hours' inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology.

Authors:  O Habler; M Kleen; S Takenaka; R Leiderer; R Pusch; M Welte; B Zwissler; K Messmer
Journal:  Intensive Care Med       Date:  1996-11       Impact factor: 17.440

2.  Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs.

Authors:  O Habler; M Kleen; B Zwissler; R Pusch; M Welte; C Vogelmeier; B Kempter; F Krombach; K Messmer
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

Review 3.  Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia.

Authors:  Christopher D Baker; Steven H Abman; Peter M Mourani
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-03-01       Impact factor: 1.349

4.  Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial.

Authors:  Beena G Sood; Virginia Delaney-Black; Jacob V Aranda; Seetha Shankaran
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

5.  Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children.

Authors:  Anna T Brown; Jennifer V Gillespie; Franscesca Miquel-Verges; Kathryn Holmes; William Ravekes; Philip Spevak; Ken Brady; R Blaine Easley; W Christopher Golden; Leann McNamara; Michael A Veltri; Christoph U Lehmann; Kristen Nelson McMillan; Jamie M Schwartz; Lewis H Romer
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

Review 6.  Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices.

Authors:  Nathan Cosa; Edward Costa
Journal:  Med Devices (Auckl)       Date:  2016-04-12

Review 7.  Phytochemicals in Human Milk and Their Potential Antioxidative Protection.

Authors:  Apollinaire Tsopmo
Journal:  Antioxidants (Basel)       Date:  2018-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.